[HTML][HTML] Resistance to TKIs in EGFR-mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies
Simple Summary Resistance to tyrosine kinase inhibitors (TKIs) of the epidermal growth
factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) constitutes …
factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) constitutes …
[HTML][HTML] Multicellular effects of STAT3 in non-small cell lung cancer: Mechanistic insights and therapeutic opportunities
Simple Summary Persistent activation of STAT3 is frequently observed in non-small cell lung
cancer and is associated with a poor prognosis. Given the multifaceted role of STAT3 …
cancer and is associated with a poor prognosis. Given the multifaceted role of STAT3 …
[HTML][HTML] Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first-or second-generation tyrosine kinase inhibitors
CT Huang, CA Lin, TJ Su, CY Yang, TH Tsai, CL Hsu… - BMC cancer, 2023 - Springer
Abstract Background The T790M mutation is the major resistance mechanism to first-and
second-generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility …
second-generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility …
[HTML][HTML] Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer
Z Liu, L Ma, Y Sun, W Yu, X Wang - Cell Death & Disease, 2021 - nature.com
Lung cancer is one of the most aggressive cancers with poor prognosis and high resistance
rate. The family of signal transducer and activator of transcriptions (STATs) appears to …
rate. The family of signal transducer and activator of transcriptions (STATs) appears to …
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer
LT Huang, SL Zhang, CB Han, JT Ma - Lung Cancer, 2022 - Elsevier
Abstract Objective Exon 19 deletion (19del) is a sensitive mutation of epidermal growth
factor receptor (EGFR) observed in non-small cell lung cancer (NSCLC), and consists of a …
factor receptor (EGFR) observed in non-small cell lung cancer (NSCLC), and consists of a …
Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with EGFR G719X/L861Q/S768I
LL Pang, JD Gan, JR Tan, YH Huang, J Liao… - Cancer, 2022 - Wiley Online Library
Background Afatinib is the only currently approved EGFR‐tyrosine kinase inhibitors for
advanced non–small cell lung cancer (NSCLC) patients with EGFR G719X/L861Q/S768I …
advanced non–small cell lung cancer (NSCLC) patients with EGFR G719X/L861Q/S768I …
[HTML][HTML] Afatinib and dacomitinib efficacy, safety, progression patterns, and resistance mechanisms in patients with non-small cell lung cancer carrying uncommon …
HS Li, SZ Wang, HY Xu, X Yan, JY Zhang, SY Lei, T Li… - Cancers, 2022 - mdpi.com
Simple Summary Afatinib has been approved for patients with lung cancer carrying
uncommon epidermal growth factor receptor gene (EGFR) mutations. Dacomitinib, another …
uncommon epidermal growth factor receptor gene (EGFR) mutations. Dacomitinib, another …
[HTML][HTML] An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
In Taiwan, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs),
gefitinib, erlotinib, and afatinib are served as first-line therapy for non-small lung cell cancer …
gefitinib, erlotinib, and afatinib are served as first-line therapy for non-small lung cell cancer …
[HTML][HTML] Risk stratification using a novel nomogram for 2190 EGFR-mutant NSCLC patients receiving the first or second generation EGFR-TKI
JWC Chang, CY Huang, YF Fang, CF Chang, CT Yang… - Cancers, 2022 - mdpi.com
Simple Summary No comprehensive and simple prognostic model based on pretreatment
factors exists for patients with epidermal growth factor receptor mutation-positive (EGFRm+) …
factors exists for patients with epidermal growth factor receptor mutation-positive (EGFRm+) …
[HTML][HTML] Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort …
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - BMC cancer, 2021 - Springer
Background Afatinib is one of the standard treatments for patients with epidermal growth
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …